RT Journal Article
SR Electronic
T1 Clarification: post-coital contraception (January 18, p 5)
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 16
OP 16
DO 10.1136/dtb.18.4.16
VO 18
IS 4
YR 1980
UL http://dtb.bmj.com/content/18/4/16.abstract
AB Wyeth have asked us to point out that the product licence for Ovran does not allow its use in post-coital contraception, and that such use is not recommended by the company. This applies equally to Schering’s Eugynon 50.